Abstract | OBJECTIVE: The aim of this study was to conduct a prospective safety and tolerability study of aripiprazole for the treatment of tics in children and adolescents with Tourette's disorder (TD). METHOD: Eleven subjects (10 males) with TD (age 9-19 years, mean 13.36, standard deviation [SD] 3.33) who did not respond or were unable to tolerate previous tic medication were treated with aripiprazole in an open-label, flexible-dosing study over 10 weeks. Tic severity was rated using the Yale Global Tic Severity Scale (YGTSS) and the Clinical Global Impressions Scale for tics (CGI- Tics) at baseline and at follow-up. RESULTS: The mean (+/-SD) daily dose for aripiprazole was 4.5 +/- 3.0 mg. Mean (+/-SD) YGTSS Global Severity scores reduced from 61.82 +/- 13.49 at baseline to 33.73 +/- 15.18 at end point; mean YGTSS total tic scores reduced from 28.18 +/- 7.74 at baseline to 16.73 +/- 7.54 at end point. Mean (+/-SD) CGI- Tic severity scores reduced from 4.45 +/- 0.52 (moderate-marked) at baseline to 3.18 +/- 0.60 (mild) at end point. On the CGI- Tic improvement scale, 10 (91%) subjects achieved 1 ("very much improved") or 2 ("much improved") at end point. Most common adverse effects included appetite increase and weight gain in 5 subjects, mild extrapyramidal effects in 7 subjects, and headaches and tiredness/ fatigue in 7 subjects; 1 subject experienced akathisia and muscle cramps. CONCLUSION:
Aripiprazole appears to be a safe and tolerable treatment in children and adolescents with TD that appears to reduce tics; it should be further investigated as a treatment option in controlled trials.
|
Authors | Gholson J Lyon, Stephanie Samar, Rahil Jummani, Scott Hirsch, Arie Spirgel, Rachel Goldman, Barbara J Coffey |
Journal | Journal of child and adolescent psychopharmacology
(J Child Adolesc Psychopharmacol)
Vol. 19
Issue 6
Pg. 623-33
(Dec 2009)
ISSN: 1557-8992 [Electronic] United States |
PMID | 20035580
(Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antipsychotic Agents
- Piperazines
- Quinolones
- Aripiprazole
- Prolactin
|
Topics |
- Adolescent
- Antipsychotic Agents
(adverse effects, therapeutic use)
- Aripiprazole
- Body Weight
(drug effects)
- Child
- Dose-Response Relationship, Drug
- Female
- Humans
- Male
- Piperazines
(adverse effects, therapeutic use)
- Prolactin
(metabolism)
- Psychiatric Status Rating Scales
- Quinolones
(adverse effects, therapeutic use)
- Severity of Illness Index
- Tics
(drug therapy)
- Tourette Syndrome
(drug therapy)
- Treatment Outcome
- Young Adult
|